Eli Lilly and Company (NYSE:LLY) Price Target Raised to $950.00

Eli Lilly and Company (NYSE:LLY) had its target price raised by Berenberg Bank from $830.00 to $950.00 in a report released on Tuesday morning,MarketScreener reports. Berenberg Bank currently has a hold rating on the stock.

Several other brokerages have also recently issued reports on LLY. Loop Capital set a $950.00 target price on Eli Lilly and Company in a research report on Monday, November 10th. Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Morgan Stanley lifted their price objective on shares of Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the stock an “overweight” rating in a report on Monday, November 24th. Leerink Partnrs upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 10th. Finally, BMO Capital Markets raised their price target on shares of Eli Lilly and Company from $930.00 to $1,100.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Three research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,087.32.

Eli Lilly and Company Trading Down 2.1%

NYSE:LLY opened at $1,011.74 on Tuesday. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,111.99. The company has a market cap of $956.48 billion, a PE ratio of 49.50, a PEG ratio of 1.15 and a beta of 0.37. The firm has a 50-day moving average of $913.15 and a 200-day moving average of $807.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company’s quarterly revenue was up 53.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Institutional Trading of Eli Lilly and Company

Several hedge funds have recently added to or reduced their stakes in LLY. Laurel Wealth Advisors LLC lifted its stake in Eli Lilly and Company by 78,621.2% in the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after purchasing an additional 11,537,661 shares during the last quarter. Norges Bank bought a new stake in shares of Eli Lilly and Company in the second quarter valued at $8,827,714,000. Nuveen LLC bought a new stake in shares of Eli Lilly and Company in the first quarter valued at $4,613,912,000. Vanguard Group Inc. lifted its position in shares of Eli Lilly and Company by 6.7% during the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock valued at $65,432,218,000 after buying an additional 4,975,395 shares during the last quarter. Finally, Capital Research Global Investors grew its stake in shares of Eli Lilly and Company by 20.9% during the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after acquiring an additional 4,332,008 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.